Investing in oncology: a biotech revolution in research, diagnosis, and treatment of cancer
Cancer will affect one in every two people in their lifetime. Yet, oncology is on the brink of a revolution, which we expect will trigger a material expansion of oncology investment opportunities. This blog explores this revolution and how to invest behind oncology, one of the largest life sciences investment themes.
• There is a revolution underway, driving significant advances in diagnoses and treatments.
• The listed company opportunity set tied to oncology continues to expand significantly, but oncology remains a complex sector which requires expertise to navigate.
• The biotech sector has recently undergone a sharp de-rating in valuations.
• Big pharma, in need of replacing imminent patent cliffs, has historically relied on M&A  at hefty premiums to drive its innovation pipeline. Big pharma’s current ‘dry powder’ is roughly equal to ~75% of the combined market cap of biotech companies  .
• We believe oncology stands out as a superior biotech segment across several criteria including growth, innovation, and prevalence.
• The Tema Oncology ETF aims to select the winners of this cancer revolution.
For a list of current fund holdings, please visit the fund web page at www.temaetfs.com/canc. All investments involve risks, including possible loss of principal. For a more complete discussion of the potential investment risks to the topics discussed below see the disclosure section at the end of the document.
What is oncology and why is it such a burden?
Oncology is the study of cancer. In cancer, some of the body’s own cells change and start to divide uncontrollably. It isn’t just one illness, but several different ones, affecting various organs or tissues. As these are the body’s “own cells”, they can evade the immune system response. Worse still, as cancerous cells mutate rapidly, the treatments we have often only work for a period before the cancer eventually evades them and progresses. Cancer eventually becomes deadly when it spreads across the body by a process called metastasis.
Cancer will afflict one in every two people at some point in their lifetime  . It is the second leading cause of death, with costs to society forecasted to be over $25 Tn globally from 2020 to 2050 .
Oncology attempts to treat cancer, through understanding its fundamental biology both in vitro (in test tubes) and in vivo (in organisms). Ultimately, the field aims to improve prevention through diagnostics and treatment through therapeutics.
What are some of the breakthroughs in cancer research and development?
A biological revolution is driving significant advances in diagnosing and treating cancer.
DNA sequencing revolution is a key underlying driver of innovation
Much of the biological revolution can be attributed to innovations in genome sequencing. Starting with the success of the Human Genome project in 2003, the cost to sequence a human genome has collapsed. Where Moore’s law predicted that the doubling of transistors would halve the cost of computing every two years, the cost of genome sequencing has progressed at an exponentially faster rate. Today a genome can be sequenced for as cheaply as $600  , helping scientific understanding in immeasurable ways.
CAR T-cell therapy
Armed with better scientific understanding, we have started to turn biological machinery to our advantage. Breakthroughs now mean that a patient’s T-cells, the hunter cells of the immune system, can be extracted, genetically engineered to detect cancers, and reinserted into the body. These types of therapies, called chimeric antigen receptor (CAR) T-cells, developed by companies like Novartis and Kite Pharmaceuticals (acquired by Gilead Sciences) are already approved for the treatment of blood cancers, such as lymphoma and chronic leukocytic leukemia.
Technologies like CRISPR gene editing, which allows precise edits to a cell’s DNA, have opened the next generation of cell therapy in two major directions. First, allogenic engineered T-cells could be available “off the shelf”, avoiding the burdensome extraction step. Second, efforts are underway to apply cell therapy to solid tumors, which are more common than blood cancers.
Detecting cancer early is vital. Thanks to years of development by companies like GRAIL and Guardant Health, we now have commercialized cancer diagnostics through a non-invasive blood test. These liquid biopsies are sensitive diagnostics that can detect cancerous genetic material circulating in the blood stream. In addition, some of these diagnostics have the promise to detect multiple cancers in otherwise healthy individuals, and even determine tumor of origin. Early intervention has a greater impact as mortality in metastatic / highly progressive disease tends to be much higher.
Improved liquid biopsies can also be used in treatment selection and post-remission monitoring. Increasingly, information from these diagnostics could improve clinical trials development.
The past decade heralded successfully commercialized antibody-based therapies that capitalized on an important breakthrough in immunology – immune checkpoints. These are essentially the brakes on our immune systems not to overreact. Cancers, by their heavy mutation loads, evade the immune system by in part acting on these brakes. By giving patients checkpoint inhibitors, like PD-1 antibodies, oncologists can remove the “cloak” that tumors use to evade the immune system. This has led to, for the first time, survival curves in some patients and in some cancers (e.g., melanoma) never converging to zero: i.e., a cure.
It is now routine to give these as first-line therapy, which has meant Keytruda, one of the PD-1 inhibitors, is currently the world’s bestselling blockbuster drug forecasted to generate $24 Bn in worldwide sales in 2023  . Despite this enormous progress, only 20% of patients respond  , leaving room for newer approaches in immuno-oncology. For example, Immunocore has pioneered a way to let T-cells target proteins inside cancerous cells, opening the possibility of engineered T-cells that could hunt down solid tumor cancers.
Today, our understanding of cancer has evolved to the point that we are able to segment patient populations and offer targeted, almost personalized, treatments. Many of these therapies act on the mutations that drive tumorigenesis and hence have the promise of higher efficacy and/or safety. Antibody technology advances have also allowed payloads to be delivered more precisely to cancer tissue. An example of this is Enhertu, which almost doubles progression free survival in a key breast cancer population  .
In general, these technologies are driving meaningful improvements in survival and quality of life, with an associated positive uplift to industry revenues.
There is a boom in R&D productivity in Oncology
These innovations are part of a boom in drug R&D productivity. The number of new molecular entities approved by the FDA in 2022 doubled from 2010  . Oncology is leading the way, taking a growing share of these approvals.
Oncology market outlook
The evolution of oncology is being driven by several long-term factors.
• First, populations are aging. The global population of individuals over the age of 60 is forecast by the UN to go up 2.5x by 2050 to nearly 2.5 billion  . Older individuals are much more prone to develop cancer, as one can see from the chart below.
• Second, the growing prevalence of obesity and other lifestyle factors represent alarming long-term drivers of cancer.
• Third, environmental factors, such as industrial pollution, are also key drivers of cancer incidence. A recent European Environmental Agency (EEA) report has estimated that pollution causes 10% of all cancer cases in Europe  .
As a result, the oncology market is forecast by IQVIA to hit $375 Bn globally by 2027  .
Exploring investment opportunities in oncology
The burst of innovation and healthy capital markets have meant the last decade has seen an almost Cambrian explosion of new oncology companies. If we plot our proprietary Oncology universe  by IPO  year, we find that 70% of public oncology companies were listed in the last decade  . This creates a larger and likely richer set of investment opportunities to pick from.
Is the oncology segment more attractive than broader biotech?
Investors might ask whether investing in a biotech benchmark, like the Nasdaq Biotechnology Index  (NBI, consisting of large and small biotech firms) or the equal weighted S&P Biotechnology Select Industry Index  (SPSIBI), might offer a better alternative.
We believe that oncology is the superior subsegment:
• Oncology has the potential to offer exposure to innovative fast-growing firms, while the NBI is dominated by slower-growing bellwether firms.
• SPSIBI, on the other hand, may have a higher risk of exposing investors to speculative cash burning companies.
• Neither index benefits from exposure to non-therapeutic areas such as diagnostics.
• We feel that biotech indices such as SPSIBI are backward-looking and overlook company quality factors such as scientific success and management track record.
• Finally, the Biden-Harris administration’s goal to halve the mortality from cancer by 2050  is a policy tailwind for the oncology space. The same can’t be said for broader indices. The NBI is potentially exposed to pricing risks because of a higher exposure to non-innovative medicines, and the SPSIBI is exposed to regulatory hot spots like rare diseases.
Is there an Oncology ETF?
CANC is the first Oncology-focused ETF in the US market. CANC is managed by an experienced portfolio manager with over 25 years of healthcare industry and investing experience. The CANC portfolio aims to be broadly exposed to breakthrough innovation and to balance risk profiles – with a mixture of emerging biotechnology firms, growing firms with inflecting revenues and more established companies. There is a keen focus on valuation and understanding risk-reward of the ever-expanding oncology investment opportunity set.
Why should I consider investing in Oncology ETF in the current environment?
We believe the biotech sector currently offers exceptional value
The biotech sector has had a difficult past two years, clocking in the worst downcycle in decades.
In our analysis, almost 25% of small biotech firms are trading at market caps below the net cash on their balance sheets i.e., negative enterprise value. Although some of these firms require cash resources to deliver their R&D programs, this is a stark reading of how far valuations have come down.
Big pharma needs to replace revenue streams and have the firepower to do it
In the next five years, large pharmaceutical firms must find a way to replace an expected $350 Bn of revenue at risk from patent expiry  . One approach is to acquire smaller innovative biotechnology firms. In our calculations big pharma today is sitting on $838 Bn of “dry powder”  to acquire these firms, representing 74% of the entire market cap of the S&P biotechnology index  .
Oncology is a key focus for future pipelines, and a slew of recent deals, like Pfizer’s acquisition of Seagen, bode well for this trend. Such deals have historically been done on average premiums of 98% as per our analysis below.
What are the risks of investing in oncology?
There are several risks for investors to consider:
• Product risk: consisting of scientific risk (the biological hypothesis doesn’t work), clinical risk (the product does not work in humans) and commercial risk (the product doesn’t produce adequate revenue). We seek to mitigate these risks by avoiding unfavorable risk-reward data read-outs, conduct expert analysis of clinical data, and model potential market sizes using third-party commercial data.
• Funding risk: arising from some biotech firms requiring additional financial resources to complete their R&D programs. The fund will seek to risk manage exposure to these firms both via rigorous balance sheet analysis and restricted position sizing.
• Regulatory risk: always present in the healthcare space. We believe the most recent Medicare pricing regulation in the US  , though negative, is a manageable risk for the industry. Oncology drugs, because of the huge unmet medical need, are classified as a protected therapeutic category under Medicare – mitigating some of the deleterious impacts from recent reforms.
The oncology revolution is accelerating with an expanding opportunity set of companies, yet expertise is required to identify the companies that will benefit from these tailwinds while diligently managing risk.
 Source: Our World In Data, 2019
 Source: Jama Network. Scope: cost of 29 cancers in 204 countries and territories
 M&A: mergers and acquisitions
 Source: Bloomberg. Dry powder defined as total Cash and Cash Equivalents on the top 20 large cap pharma company balance sheets as of 31/12/2022 plus total Free Cash Flow generation over the next three years as forecast by consensus on Bloomberg. Biotech companies universe defined as the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index. is designed to measure the performance of narrow GICS sub-industries. The Index comprises stocks in the S&P Total Market Index that are classified in the GICS biotechnology sub-industry.
 NCI (National Cancer Institute), 2020, USA only. 40% of Americans are forecasted to be diagnosed with cancer in their lifetime.
Source: National Human genome Research Institute
 Source: Evaluate Pharma & Evaluate Vantage, Global sales 2023. Includes sales booked by global partners, where relevant.
 Source: Biomarker Research, 2020, “Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives”.
 Source: American Society of Clinical Oncology, 2022, “Novel Antibody-Drug Conjugate Doubles Progression-Free Survival in Metastatic Breast Cancer With Low HER2 Expression Levels”
 Source: CEDR a department of FDA, 2021.
 Source: UN (2017). World Population Prospects: the 2017 Revision
 Source: European Environment Agency, 2022. " Exposure to pollution causes 10% of all cancer cases in Europe”
 Source: IQVIA Oncology Link, April 2023. Forecasts are inherently limited and should not be relied upon when making investment decisions. There is no guarantee projected growth will occur. In addition, there is no guarantee it will translate to positive fund performance.
 Tema proprietary universe defined as publicly listed companies that derive at least 50% of revenues from oncology. Internal research and analysis based on company disclosure (such as 10-K filings, company presentations, capital markets day presentations) and other publicly available sources (e.g., sell-side research, Biotechnology industry publications etc.) were used to make this assessment.
 IPO: initial public offering, An initial public offering or stock launch is a public offering in which shares of a company are sold to institutional investors and usually also to retail investors.
 Source: Bloomberg, Tema analysis
 Nasdaq Biotechnology Index (NBI): The NASDAQ Biotechnology Index contains securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria.
 The S&P Biotechnology Select Industry Index is designed to measure the performance of narrow GICS sub-industries. The Index comprises stocks in the S&P Total Market Index that are classified in the GICS biotechnology sub-industry.
 Source: The White House, 2023
 Source: Evaluate Pharma Aug 2022. Encompasses entire pharmaceutical industry, not just oncology. Timelines are estimates based on key patent expirations or patent settlement agreements, and the life of a brand can be lengthened or shortened unexpectedly due to various factors. Forecasts are inherently limited and should not be relied upon when making investment decisions. There is no guarantee projected growth will occur.
Dry powder defined as total Cash and Cash Equivalents on the top 20 large cap pharma company balance sheets as of 31/12/2022 plus total Free Cash Flow generation over the next three years as forecast by consensus on Bloomberg. ~75% of small and medium sized biotech companies of the S&P Biotechnology Select Industry Index market cap.
 Source: Bloomberg. The S&P Biotechnology Select Industry Index. is designed to measure the performance of narrow GICS sub-industries. The Index comprises stocks in the S&P Total Market Index that are classified in the GICS biotechnology sub-industry.
 Source: Centers for Medicare & Medicaid Services. The new drug law makes improvements to Medicare that will expand benefits, lower drug costs, keep prescription drug premiums stable, and improve the strength of the Medicare program.
Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s prospectus or summary prospectus, which may be obtained by visiting www.temaetfs.com.
Read the prospectus carefully before investing
Investing involves risk including possible loss of principal. There is no guarantee the adviser’s investment strategy will be successful.
Sector Focus Risk: Oncology companies are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company’s valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable. The stock prices of oncology companies have been and will likely continue to be very volatile. The costs associated with developing new drugs can be significant, and the results are unpredictable. Newly developed drugs may be susceptible to product obsolescence due to intense competition from new products and less costly generic products. Moreover, the process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals will be obtained or maintained.
Investing in foreign and emerging markets involves risks relating to political, economic, or regulatory conditions not associated with investments in U.S. securities and instruments. In addition, the fund is exposed to currency risk.
Because the Fund evaluates ESG factors to assess and exclude certain investments for non-financial reasons, the Fund may forego some market opportunities available to funds that do not use these ESG factors.
Tema Global Limited serves as the investment adviser to Tema Oncology ETF (the “Fund”), and NEOS Investments, LLC serves as a sub-adviser to the Fund. The Fund is distributed by Foreside Fund Services LLC, which is not affiliated with Tema Global Limited nor NEOS Investments, LLC. Check the background of Foreside on FINRA’s BrokerCheck.
For inquiries: firstname.lastname@example.org